Logo image
Adverse Events and Safety of SARS-Cov2 Vaccines: What’s New and What’s Next
Journal article   Open access   Peer reviewed

Adverse Events and Safety of SARS-Cov2 Vaccines: What’s New and What’s Next

K.B. Corey, G. Koo and E.J. Phillips
The Journal of Allergy and Clinical Immunology: In Practice, Vol.10(9), pp.P2254-P2266
2022
pdf
SARSCov21.52 MBDownloadView
Author’s Version Open Access

Abstract

Just over one year following rollout of the first vaccines for coronavirus disease 2019 (COVID-19), 572 million doses have been administered in the United States. Comparatively to the number of vaccines administered, adverse effects such as anaphylaxis have been rare, and seemingly, the more serious the effect, the rarer the occurrence. Despite these adverse effects, there are few, if any, true contraindications to COVID-19 vaccination and most individuals recover without further sequelae. This review provides guidance for the allergist/immunologist regarding appropriate next steps based on patient’s known allergy history or adverse reaction after receipt of COVID-19 vaccine in order to assist in safe global immunization.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

3 File views/ downloads
64 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.75 Blood Clotting
1.75.2119 Heparin-Induced Thrombocytopenia
Web Of Science research areas
Allergy
Immunology
ESI research areas
Clinical Medicine
Logo image